Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells.
|
18096875 |
2008 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF reduced susceptibility to CL-387,785 in H1975 cells.
|
20008840 |
2010 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A body of past research shows that increased levels of HGF and/or overexpression of c-Met are associated with poor prognosis in several solid tumors, including lung cancer, as well as cancers of the head and neck, gastro-intestinal tract, breast, ovary and cervix.
|
30134579 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result of ROC analysis, serum cMET (AUC: 0.892) and HGF protein (AUC: 0.784) were diagnosed in lung cancer patients (Fig.1).
|
31104010 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
|
29253515 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cetuximab sensitivity and signal transduction in lung cancer cells were examined in the presence or absence of HGF, HGF-producing fibroblasts, and cells tranfected with the HGF gene in vitro and in vivo.
|
22089117 |
2012 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
E7050 circumvented resistance to all of the reversible, irreversible, and mutant-selective EGFR-TKIs induced by exogenous and/or endogenous HGF in EGFR mutant lung cancer cell lines, by blocking the Met/Gab1/PI3K/Akt pathway in vitro.
|
22317763 |
2012 |
Malignant neoplasm of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
|
24297483 |
2014 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition.
|
28888686 |
2017 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher serum/plasma HGF levels are associated with therapy resistance and/or metastasis, while lower HGF levels are associated with progression-free survival and overall survival after treatment with targeted drugs in lung cancer, gastric cancer, colon cancer, and malignant melanoma.
|
28064454 |
2017 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, these findings provided preclinical evidence that crizotinib can be used in the treatment of HGF-induced resistance to gefitinib in EGFR mutant lung cancer.
|
23962905 |
2013 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, a novel HGF regulatory pathway in lung cancer involving micro-RNAs (miRNAs/miR) is described.
|
30569179 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Met activation by gene amplification and its ligand, hepatocyte growth factor (HGF), imparts resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer.
|
24828661 |
2014 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines.
|
16819504 |
2007 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, ETS2 was found to significantly inhibit lung cancer cell growth, migration, and invasion (P < 0.05), and microarray and pathways analysis revealed significant (P < 0.001) activation of the HGF pathway following ETS2 knockdown.
|
23659968 |
2013 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, although different mechanisms eliciting the aberrant MET-associated oncogenic stimulus have been detected in lung cancer (such as gene amplification, increased gene copy number, mutations and MET/HGF overexpression), to date no clinically impactful results have been achieved with anti-MET tyrosine kinase inhibitors and monoclonal antibodies in the context of an unselected or MET enriched population.
|
28843992 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that both autocrine and paracrine functions of HGF are likely to contribute to the pathobiology of lung cancer in vivo.
|
11172296 |
2001 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study for the first time indicated the new function of miR-1-3p and miR-206 in overcoming HGF-induced gefitinib resistance in EGFR mutant lung cancer cell.
|
29664235 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, miR-206 inhibits HGF-induced EMT and angiogenesis in lung cancer by suppressing c-Met/PI3k/Akt/mTOR signaling.
|
26919096 |
2016 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The co-expression of HGF and Met is common among nonsmall-cell lung cancers, especially adenocarcinoma.
|
10935508 |
2000 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of the Hsp90 inhibitor 17-demethoxygeldanamycin (17-DMAG) on the growth of lung cancer cells resistant to the EGFR-TKI were examined in the presence and absence of HGF, and in cells transfected with the HGF gene in vitro and in vivo.
|
22592212 |
2012 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The median level of HGF in plasma at baseline was 140 pg/ml and was significantly higher in the advanced stage of cancer and in smokers and predicted poor survival as determined using 315 plasma samples from 225 lung cancer patients.
|
25338771 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers.
|
23401458 |
2013 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These observations indicate that signals from oncogenic drivers (EGFR signaling in EGFR -mutant lung cancer and ALK signaling in EML4-ALK lung cancer) and ligand-triggered bypass signals (HGF-Met and EGFR ligands-EGFR, respectively) must be simultaneously blocked to avoid the resistance.
|
22435662 |
2012 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations provide a rationale for targeting HGF in EGFR-TKI resistance in EGFR mutant lung cancer.
|
22052230 |
2011 |